Changing patterns in the prevalence and management of cardiovascular risk factors in India and their comparison with the rest of the world along with clinical outcomes at 5-year: An analysis of stable coronary artery disease patients from The Prospective Observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry

Abstract

ObjectivePresent paper describes trends in prevalence and control of cardiovascular risk factors and clinical outcomes at 5-years for CLARIFY Indian cohort compared with rest of the world (ROW).MethodCLARIFY is an international, prospective-observational, longitudinal cohort study in stable coronary artery disease outpatients. The 5-year data of both cohorts were compared, and evaluated.ResultsIn Indian cohort, the angina prevalence declined significantly. There are few favorable changes in the pattern of receiving guideline-recommended therapy over 5 years, and the Indian cohort exhibited significantly lower adverse clinical outcomes than ROW.ConclusionThe 5-year trend of CLARIFY India registry indicate varying trends in prevalence and control of cardiovascular risk factors, the need for approaches to improve control of all modifiable risk factors, and increase in long-term use of essential primary and secondary prevention medications in clinical practice as emphasized in the latest Indian guidelines for management of stable CAD.

Demographic profile, clinical characteristics and medical management patterns of Indian coronary artery disease patients: a nationwide urban-based, real-world, retrospective, observational electronic medical record study– report of baseline data

“…Additionally, laboratory findings suggested an overall elevated mean level of HbA1C in both ACS and SIHD (8.06 % in ACS and 8.5 % in SIHD p<0.05) similar to trends observed previously in Indian setting [9] In terms of therapies prescribed, current study data shows that overall, the choice of therapies is very similar for both ACS and SIHD in Indian settings. However, amongst the antiplatelets clopidogrel (24% in ACS and 41.9% in SIHD p<0.05) appears to be more frequently used in SIHD, while prasugrel (6.8% in ACS and 2.4% in SIHD, p<0.05) and ticagrelor (20.8% in ACS and 5.5% in SIHD, p<0.05) are more frequently used in ACS (Figure 4A).…”

Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation

“…ст. (ОР 1,41; 95% ДІ 1,24-1,61) були пов'язані з більш високим ризиком кінцевих точок (серцево-судинна смерть, інфаркт міокарда або інсульт) [41]. Для ілюстрації наводимо дослідження SPRINT (Systolic Blood Pressure Intervention Trial).…”

Revisiting the Global Overfat Pandemic

“…India, Pakistan, Bangladesh, Bhutan and other South Asian countries have a significant and increasing prevalence of excess body fat, cardiometabolic impairment, and high burden of disease associated with insulin resistance and diabetes, hypertension, hypertriglyceremia and low serum levels of high density lipoprotein (HDL) (44,45). For the same BMI, body fat is 7-8% higher for Indians compared to Whites (46).…”